Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
GLP-1 persistence in the US military
A 10,649-patient Military Health System database study found tirzepatide had 81.9% one-year persistence vs 70.7% for semaglutide and 34.2% for liraglutide.
GLP-1 Agonists in Older Adults: Key Issues
Sarcopenia, polypharmacy, and limited age-specific data shape GLP-1 receptor agonist use in older adults with obesity and type 2 diabetes.
MASH drugs: resmetirom and semaglutide
Resmetirom and semaglutide now hold conditional approvals for MASH. Here is what the trial evidence shows and where gaps remain.
Real-world semaglutide: dose and dropout
A Danish study of 206 patients found 38% permanently stopped semaglutide within 12 months; 70% of continuers used doses below the 2.4 mg approved maximum.
SGLT2 and GLP-1 on arrhythmias: 32 trials
A 2026 network meta-analysis of 32 trials finds an exploratory VA signal for empagliflozin and consistent HHF benefits for SGLT2 inhibitors.
HbA1c alone cannot prove semaglutide parity
A July 2026 letter argues that matching semaglutide on HbA1c over 24 weeks does not establish full therapeutic interchangeability with the originator.
GLP-1 telehealth prescribing oversight
A Yale JAMA secret-shopper study flagged GLP-1 telehealth sites for thin clinical oversight. Here is what peer-reviewed evidence shows about platform quality.
Syringes for subcutaneous peptide injection
Syringe volume, needle gauge, and length each affect subcutaneous delivery. Here is what GLP-1 prescribing information and CDC injection safety guidance say.
Is tesamorelin banned in sport? WADA status
Tesamorelin is a GHRH analogue prohibited under WADA S2 in and out of competition. Here is what that means and why the TUE picture is unusual.
What is tesamorelin?
Tesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy. Plain-English guide to its mechanism, one approved indication, and what the Phase 3 trials found.
Tirzepatide dosing: what the trials used
A trial-by-trial map of the dose escalation schedules used across the SURPASS and SURMOUNT programmes, with what each schedule produced at the primary endpoint.
Tirzepatide history: discovery to approval
Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.